Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.42 |
| ▸ | CCR5 | P51681 | 2/20 | 0.42 |
| ▸ | CCR8 | P51685 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.40 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.40 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | GPR39 | O43194 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3279738 | 0.89 | MAPK14 (0.43) | CCR1CCR5CCR8MAPK14LIMK1 | |
| SCHEMBL13385480 | 0.89 | CCR1 (0.38) | CCR1CCR5CCR8MAPK14LIMK1 | |
| SCHEMBL13385471 | 0.88 | IDH1 (0.39) | CCR1CCR5CCR8SMN1; SMN2L3MBTL1 | |
| SCHEMBL13385490 | 0.85 | NR4A2 (0.43) | CCR1CCR8NPC1NR4A2MEN1 | |
| SCHEMBL13385473 | 0.85 | IDO1 (0.37) | CCR1CCR5CCR8MAPK14CYP1A2 | |
| SCHEMBL13385481 | 0.83 | CCR1 (0.43) | CCR1CCR5CCR8MAPK14LIMK1 | |
| SCHEMBL3280715 | 0.82 | CCR1 (0.51) | CCR1CCR5CCR8CYP1A2SMN1; SMN2 | |
| SCHEMBL3277360 | 0.82 | NR4A2 (0.35) | MAPK14LIMK1LIMK2NR4A2MEN1 | |
| SCHEMBL13385493 | 0.82 | CYP1A1 (0.36) | CYP1A2NR4A2 | |
| SCHEMBL3279741 | 0.81 | NR4A2 (0.42) | CCR1CCR5CCR8MAPK14SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7695728-B2 | 2-substituted pyridines, processes for their preparation and their use for controlling harmful fungi | BASF AKTIENGESELLSCHAFT (DE) | 2010-04-13 | — | — | US | disclosed |
| US-7695728-B2 | 2-substituted pyridines, processes for their preparation and their use for controlling harmful fungi | BASF AKTIENGESELLSCHAFT (DE) | 2010-04-13 | — | — | US | disclosed |
| EP-1761516-B1 | 2, 4, 5, 6-SUBSTITUTED PYRIMIDINES, METHOD FOR THE PRODUCTION AND USE THEREOF FOR COMBATING PARASITIC FUNGI | BASF AG (DE) | 2007-11-28 | — | — | EP | disclosed |
| US-20070259919-A1 | 2-Substituted Pyridines, Processes for their Preparation and Their Use for Controlling Harmful Fungi | BASF AKIENGESELLSCHAFT (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259919-A1 | 2-Substituted Pyridines, Processes for their Preparation and Their Use for Controlling Harmful Fungi | BASF AKIENGESELLSCHAFT (DE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259919-A1 | 2-Substituted Pyridines, Processes for their Preparation and Their Use for Controlling Harmful Fungi | CYP4X1, CYCS, CYP2S1 | CCR1 417/4885CCR5 816/4885CCR8 2425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.